Non-small-cell lung cancer (NSCLC) has become the most lethal human cancer because of the high rate of metastasis. Hence, clarifying the molecular mechanism underlying NSCLC metastasis is very important to improve the prognosis of patients with NSCLC. Long non-coding RNAs (LncRNAs) are a class of RNA molecules longer than 200 nucleotides, which can participate in diverse biological processes. About 18% of human LncRNAs were recently found to be associated with tumours. Many studies indicated that aberrant expression of LncRNAs played key roles in the progression and metastasis of NSCLC. According to the function in tumours, LncRNAs can be divided into two classes: oncogenic LncRNAs and tumour-suppressor LncRNAs.
| INTRODUC TI ON
The lung cancer is the leading cause of cancer-related death in China and is responsible for more than 1 million deaths around the world annually. 1, 2 Despite there are many methods to treat the lung cancer cases, the overall survival is still poor because patients were at advanced stages when diagnosed. 3 Non-small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma and large cell carcinoma, composes about 85% of lung cancers, and more than half of patients with newly diagnosed NSCLC have metastatic disease. 4 Because of the high rate of metastasis, NSCLC has become the most lethal human cancer. 5 Thus, understanding the molecular basis underlying NSCLC progression and metastasis is important to improve the treatment and prognosis of patients with NSCLC.
Long non-coding RNAs (LncRNAs) are a class of RNA molecules longer than 200 nucleotides, which can participate in diverse biological processes, including cell differentiation, modulation of apoptosis and invasion, reprogramming stem cell pluripotency and parental imprinting. 6 The main characteristics of LncRNAs are that these RNAs are able to be transcripted, but cannot be translated into proteins, so they exert their respective biological functions at RNA level. 7 Meanwhile, their abnormal expression is closely related to a variety of diseases, especially tumours. 8 About 18% of human LncRNAs were recently found to be associated with tumours. 9 Many studies demonstrated aberrant expression of LncRNAs played key roles in the progression and metastasis of NSCLC. [10] [11] [12] According to the function in tumours, LncRNAs can be divided into two classes:
oncogenic LncRNAs and tumour-suppressor LncRNAs. Nowadays, LncRNAs have become a new therapeutic target for treating NSCLC metastasis.
More and more evidence indicated that LncRNAs were involved in tumour invasion and metastasis. Hence, our main purpose is to review recent literature on the relationship between LncRNAs and the metastasis of NSCLC.
| MAIN MOLECUL AR MECHANIS M OF LncRNA TO REG UL ATE THE ME TA S TA S IS OF N SCLC

| LncRNAs interact with miRNAs as ceRNAs
Many researchers have proved that LncRNAs could regulate the level of miRNAs, which in turn regulate the expressions of miRNA's target genes. LncRNAs might compete with miRNAs as miRNA sponges in tumour progression. Competing endogenous RNA (ceRNA) theory indicated that RNA transcriptions included LncRNAs communication through a new manner mediated by microRNA response elements (MREs). 13 Here, we listed some LncRNAs functioned as ceRNAs, including oncogenic LncRNAs and tumour-suppressor LncRNAs.
| Oncogenic LncRNAs
LncRNA histocompatibility leucocyte antigen complex P5 (HCP5), which is transcriptional regulated by SMAD3 in NSCLC cells, contains miR-203 response elements. MiR-203 expression was down-regulated in NSCLC and negatively correlated with clinical tumour-node-metastasis (TNM) stages. 14 ZNFX1 antisense RNA 1 (ZFAS1), a LncRNA, originally identified a regulator of mammary development. 19 Tian et al discovered that ZFAS1 was up-regulated in NSCLC tissues and higher expression in more advanced tumour tissues. 20 It was demonstrated that ZFAS1 exerted as ceRNA to enhance the expression of proliferation, invasion and metastasis-related genes, such as ZEB1, MMP-14, MMP16, BMI1, Sp1 and ZEB2 by competitively sponging miR-150, miR-200b or miR-200c. 21, 22 HMMR-AS1, as a carcinogen, is involved in advanced TNM staging, greater tumour volume and positive lymph node metastasis because of its high expression. Cai et al found HMMR-AS1 functioned as a ceRNA of miR-138, and the high expression of miR-138 caused the repression of its endogenous target SIRT6. 23 SIRT6 is a direct target of miR-138, and knockdown of SIRT6 in NSCLC cells could increase the paclitaxel sensitivity. 24 HMMR-AS1 could be considered as a potential target for the diagnosis and treatment of NSCLC.
SUMO1P3, located at human chromosome 1q23.2, is firstly identified for its high expression in gastric cancer tissues. 25 Zhang et al confirmed SUMO1P3 expression was significantly increased in NSCLC cancer tissues and cell lines. Meanwhile, the expression level of SUMO1P3 in metastatic lymph node specimens was up-regulated in comparison with primary NSCLC tissue specimens. 26 They also found SUMO1P3 promoted NSCLC cell migration and invasion by repressing miR-136, 26 which directly targeted Smad2 and Smad3 to inhibit epithelial-mesenchymal transition (EMT) process in lung cancer cells. 27 LncRNA H19 was the first identified LncRNA in 1990. 28 Although it was reported that H19 was frequently overexpressed in lung cancer and related to cell proliferation, 29 31 Additionally, previous studies showed that down-regulation of MMP15 repressed invasion and metastasis in various cancers. 32, 33 Long non-coding RNA NNT-AS1, as a new LncRNA, was transcribed in the opposite direction of nicotinamide nucleotide transhydrogenase (NNT). Shen et al showed that the expression of NNT-AS1 was up-regulated in NSCLC tissues and cell lines.
High NNT-AS1 expression was associated with advanced tumour stage and lymph node metastasis of patients with NSCLC. 13 They also identified NNT-AS1 could function as a ceRNA by sponging miR-129-5p in lung cancer. Other research discovered that miR-NA-129-5p suppressed lung cancer cell proliferation and invasion through targeting microspherule protein 1, E-cadherin and vimentin. 34 In addition to the above LncRNAs, many studies revealed that other oncogenic LncRNAs, which could play their roles as ceRNAs, were associated with the NSCLC TNM stage and had higher expression in NSCLC than normal tissues. In Table 1 , we listed some other oncogenic LncRNAs competed with miRNAs as miRNA sponges, thereby regulating the downstream targets to promote NSCLC metastasis.
| Tumour-suppressor LncRNAs
LncNONHSAT081507.1 (LINC81507) was first identified by Peng et al using Agilent Human LncRNA Array. 44 Recently, Peng et al found reduced expression of LINC81507 resulted in cell growth, proliferation, migration and EMT in NSCLC cells, whereas ectopic overexpression of LINC81507 resulted in the opposite effects both in vitro and in vivo. 45 LINC81507 acted as a ceRNA for miR-199b-5p through directly binding and interfering miR-199b-5p-mediated regulation of CAV1 to reduce migration and invasion. In conclusion, LINC81507 served as a tumour suppressor gene in NSCLC.
The LncRNA growth arrest-specific transcript 5 (GAS5), a tumour suppressor gene, was significantly down-regulated in NSCLC tissues and cell lines, and elevated expression of GAS5 inhibited cell proliferation and induced apoptosis in NSCLC cells. 46 Dong et al demonstrated that down-expression of GAS5 obviously induced NSCLC migration and invasion. GAS5 acted as a ceRNA of miR-205 and down-regulated miR-205 to suppress lung cancer progression-related phenotypes via targeting the PTEN mRNA 3'-UTR to inhibit its translation. 47 
| LncRNAs bind with target proteins
LncRNAs can promote or inhibit the metastasis of NSCLC by directly binding with the target proteins.
| Oncogenic LncRNAs
BCYRN1 (brain cytoplasmic RNA 1, also known as BC200), a 200-nucleotide LncRNA, was found highly expressed in some carcinomas of the breast, cervix, oesophagus, lung, ovary, etc, but normally not detectable in the corresponding normal tissues. 48 Hu et al found BCYRN1 was the target gene of c-MYC and could mediate cell migration and invasion in NSCLC via influencing the expressions of MMP9 and MMP13. 49 In conclusion, BCYRN1
Oncogenic LncRNAs Target miRNA Downstream targets Reference
LncRNA NR2F2-AS1 miR-320b BMI1 35 LncRNA TTN-AS1 miR-4677-3p ZEB1 36 LncRNA XLOC_008466 miR-874 MMP2/XIAP 37 LncRNA CAR10 miR-203/miR-30 SNAI 38 LncRNA urothelial carcinomaassociated 1 (UCA1) miR-193a-3p ERBB4 39 LncRNA NEAT1 miR-181a-5p HMGB2 40 LncRNA SNHG7 miR-193b FAIM2 41 LncRNA X inactivate-specific transcript (XIST) miR-367 ZEB2 42 HOXD antisense growth associated long non-coding RNA (HOXD-AS1) could secrete S100A9 to recruit myeloid-derived suppressor cells (MDSCs), thereby promoting cancer growth and forming a special pre-metastatic immunosuppressive niche. 53 Liu et al discovered that LINC00852 targeted S100A9 to activate the MAPK signalling pathway, thereby contributing to the formation of a metastatic microenvironment, enhancing NSCLC cell migration and invasion, and eventually facilitating spinal metastasis. 54 LINC00511 was a newly identified LncRNA, which was up-regulated in human breast cancer as an oncogene. 55 Sun et al demonstrated that LINC00511 was highly up-regulated in both NSCLC tissues and cell lines. Furthermore, LINC00511-mediated oncogenic effects were partially through its epigenetically silencing of the p57 expression via directly binding with enhancer of zeste homolog 2 (EZH2). 56 In addition to these above LncRNAs, there were many other oncogenic LncRNAs, which could play their inducing NSCLC metastasis by indirectly influencing signal pathways transduction via binding with proteins. In Table 2 , we listed some other oncogenic LncRNAs and their target proteins.
| Tumour-suppressor LncRNAs
SPRY4 intronic transcript 1 (SPRY4-IT1), derived from an intron of SPRY4 gene, 63 was also a tumour suppressor gene. Wen et al found that the SPRY4-IT1 expression was significantly lower whereas EZH2 expression was higher in NSCLC tissues. SPRY4-IT1 and EZH2 showed a negative interaction in patients with NSCLC. EZH2 may promote the invasion and migration of NSCLC cells by inhibiting the SPRY4-IT1 expression. 64 LncRNA NORAD was discovered to exploit a novel mechanism for regulating protein function. 65, 66 Tan et al indicated that LncRNA NORAD was down-regulated in lung cancers and that NORAD low expression was associated with lymph node metastasis and poor prognosis. 67 Mechanistically, NORAD exploited its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing the associated pro-metastatic signalling network of S100P.
LncRNA AK126698, a tumour suppressor in NSCLC progression, was found that its expression was lower in cisplatin-resistant A549/DDP cells compared with parental A549 cells. 68 
| LncRNAs participate in the transduction of different signal pathways
Signal pathways play very important role in regulating progression and metastasis of tumour, such as Wnt/β-catenin,
TA B L E 2 Other oncogenic LncRNAs and their target proteins inducing NSCLC metastasis
Oncogenic LncRNAs Target proteins Reference
LncRNA HOXA-AS2 IGF2 57 LncRNA Myocardial infarction-associated transcript (MIAT) TDP43 58 LncRNA PXN-AS1-L PXN 59 LncRNA LINC00312 Y-Box Binding Protein 1 (YBX1) 60 LncRNA LINC00707 CDC42 61 LncRNA MALAT1 TDP43 62 PTEN/AKT and Akt/mTOR. Recent studies confirmed that many LncRNAs could exert their regulating NSCLC metastasis function by influencing the transduction of different signal pathways.
| STAT3 signal pathway
LINC01288, located on chromosome 8p12, was first reported by Bian et al as an oncogenic factor for NSCLC. 72 LINC01288 could increase viability and migration of NSCLC cell lines and enhance xenograft tumour growth and metastasis. Mechanistic study showed that LINC01288 could interact with interleukin-6 (IL-6) mRNA and increase its stability. The increased expression and secretion of IL-6 activated STAT3 signalling and therefore promoted the progression and metastasis of NSCLC.
LncRNA tyrosine kinase non-receptor 2 antisense RNA 1 (TNK2-AS1), a potential oncogenic LncRNA, was frequently up-regulated in NSCLC tissues and cell lines. Angiogenesis is one of the hallmarks for tumorigenesis and prognosis. 73 Wang et al demonstrated that TNK2-AS1 promoted NSCLC metastasis and interacted with STAT3 to increase its protein stability by protecting it from proteasome-mediated degradation. STAT3 could also bind with TNK2-AS1 promoter to trigger its transcription. The positive feedback loop between STAT3 and TNK2-AS1 therefore activated STAT3 signal pathway by elevating VEGFA expression to induce angiogenesis. 74
| Wnt/β-catenin signal pathway
Clinically, Wnt/β-catenin pathway activation predicts increased risk of tumour recurrence in patients with NSCLC. 75 MIR31HG was a LncRNA, identified as >2166 nucleotides in length. 76 Recent studies showed that increased MIR31HG expression increased gefitinib resistance in NSCLC lines through the EGFR/PI3K/AKT signalling pathway. 77 Zheng et al also discovered MIR31HG could promote the invasion of NSCLC by activating the Wnt/β-catenin signalling pathway. 78 Brain cytoplasmic RNA 1 (BCYRN1) was a 200-nucleotide
LncRNA that had been reported to be up-regulated in many malignant tumours, such as lung cancer, breast cancer and ovary carcinoma. 48 LncRNA ASAP-IT1, located in chromosome 8q24.21 in whole length of 1179bp, was initially found in ovarian cancer for its abnormal expression. 84 LncRNA small nucleolar RNA host gene 1 (SNHG1) was found overexpressed in diverse cancers, such as liver carcinoma, prostate cancer and NSCLC. [91] [92] [93] Zhang et al discovered that SNHG1 could promote ZEB1 protein expression by inhibiting the expression of TAp63, which was one of the isoforms of p63. 94 It confirmed that SNHG1 might induce the NSCLC metastasis through activating the TAp63/ZEB1 signalling pathway.
MetaLnc9, as a metastasis-related LncRNA, was identified to be obviously up-regulated in highly metastatic cells and NSCLC tumour tissues, and its expression correlated with distant metastasis and TNM.
Yu et al indicated that MetaLnc9 could interact with the glycolytic kinase PGK1 and prevent its ubiquitination in NSCLC cells, resulting in activation of the oncogenic AKT/mTOR signalling pathway. 95 NF-κB interacting LncRNA (NKILA), encoded by a gene at chromosome 20q13 just near by the prostate transmembrane protein androgen induced 1 (PMEPA1), 96 was increased by NF-κB in breast cancer. 97 Recently, Lu et al discovered that NKILA expression was negatively associated with tumour metastasis in patients with NSCLC, and the expression of NKILA was regulated through classical TGF-β signal pathway, which subsequently inhibited migration and invasion of NSCLC cells through interfering NF-κB/Snail signal pathway in NSCLC cells. 98 FER1L4, a novel LncRNA, was first identified that its down-regulated expression in human gastric cancer. 99 Gao et al also found that FER1L4 was down-regulated in NSCLC in vivo and in vitro, and overexpression of FER1L4 could inhibit cell metastasis through regulating the PI3K/Akt signal pathway. 100 Many studies indicated that the PI3K/Akt signalling was aberrantly activated in human malignancies and was associated with tumour metastasis and drug resistance. 101 
| MAIN REG UL ATING MANNER OF LncRNA S TO INFLUEN CE THE ME TA S TA S IS O F N SCLC
| Regulate the progression of epithelialmesenchymal transition (EMT)
The EMT is closely related to the high invasiveness and metastasis of cancer cells, including NSCLC. 102 More and more evidence indicates that LncRNAs are involved in tumour invasion and metastasis by regulating EMT.
LncRNA HOX transcript antisense RNA (HOTAIR) exhibited significantly higher expression in the tumour tissues than the adjacent non-tumour tissues in patients with NSCLC. 103 In lung cancer cells, HOTAIR was required for the expression of matrix metalloproteinases that break down the extracellular matrix to pave the path. 104, 105 Taken together, HOTAIR was induced by EMT stimuli, and such an induction in turn promoted the gene expression programme that resulted in EMT. 106 HOTAIR also could potentially regulate lung cancer metastasis through physical interactions with E3 ubiquitin ligases and their corresponding substrates. 106 LncRNA activated by TGF-β (ATB) was first identified in liver cancer. 107 Many studies showed that ATB promoted malignancy in many kinds of cancers, including breast cancer, glioma and colon cancer. [108] [109] [110] Recently, Wei et al demonstrated that ATB expression was significantly increased in NSCLC tissues and cell lines, compared with normal controls. 111 Knockdown of ATB in NSCLC cell lines inhibited the metastasis of lung cancer cells. They also found F I G U R E 1 The main mechanism of different LncRNAs to regulate NSCLC metastasis. There are three main mechanism, including: (a) LncRNAs interact with miRNAs as ceRNAs; (b) LncRNAs bind with target proteins; and (c) LncRNAs participate in the transduction of different signal pathways. Then, LncRNAs can exert their function to regulate the metastasis of NSCLC through influencing the progression of EMT and the properties of CSC that suppression of ATB increased the expression of E-cadherin, while decreasing the expression of N-cadherin, suggesting that ATB could influence the migratory ability of NSCLC by EMT.
Besides, many other oncogenic LncRNAs were also confirmed to promote the metastasis of NSCLC by inducing EMT, such as LncRNA colon cancer-associated transcript 1 (CCAT1), LncRNA HNF1Aantisense 1 (HNF1A-AS1) and LncRNA LINC00460.
| Influence the properties of cancer stem cell (CSC)
Cancer stem cells (CSCs) play an important role in maintaining capacity of tumour metastasis, invasion and recurrence. 112 Because
CSCs contain the self-renewal abilities which are similar to the normal stem cells, targeting CSCs also can become an effective strategy to treat cancers. 113 Linc00662, a newly discovered LncRNA, had a strong correlation with lower overall survival rate and higher lymph node metastasis rate of patients with lung cancer. Lin28, as an RNA-binding protein and a reprogramming factor, can promote the tumourigenesis and progression in many human cancers. 118 Evidence indicated that Lin28 also could participate in CSC regulation. 119 Recently, Gong et al demonstrated that Linc00662 not only induced cell migration and invasive ability but also elevated the CSC percentage in NSCLC cells by the interaction with its downstream factor Lin28. 120 According to our review, the molecular mechanism of LncRNAs regulating NSCLC metastasis mainly includes three aspects as to one LncRNA, the molecular mechanism may contain many aspects. For example, LncRNA-MALAT1, which is highly conserved among mammals, could not only competitively bind with miR-145-5p, 121 miR-204 122 and miR-206 123 as a ceRNA, but also activate Akt/mTOR signalling pathway in order to induce the metastasis of NSCLC. 123 The same LncRNA may have different molecular mechanism in diverse tumours. But until now, the studies in LncRNAs are only at the experimental level. Therefore, ongoing and future studies are expected to clarify the LncRNAs particular regulatory mechanism of inhibiting the metastasis of NSCLC and explore new drugs targeting LncRNAs. 
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